Myriad Genetics, Inc., a leading provider of genetic testing and precision medicine services, has announced the development of a range of molecular diagnostic tests for use in oncology, women's health, and mental health applications both in the United States and internationally. These include the MyRisk Hereditary Cancer Test, which assesses the risks for hereditary cancers through advanced DNA sequencing techniques, and the BRACAnalysis CDx Germline Companion Diagnostic Test, which helps to determine the appropriate therapy for cancer patients with specific germline BRCA variants. The company is also offering the MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. Other notable products include the Prolaris Prostate Cancer Prognostic Test, which utilizes RNA expression tumor analysis to assess the aggressiveness of prostate cancer; the EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; and the Prequel Prenatal Screen, which is a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. Myriad Genetics, Inc. is also offering the Foresight Carrier Screen, which is a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring. Lastly, the GeneSight Psychotropic Mental Health Medication Test is a DNA genotyping test aimed at aiding psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic partnership with Illumina, Inc. and Intermountain Precision Genomics to further improve their offerings. The company, which was founded in 1991 and is headquartered in Salt Lake City, Utah, is primed to continue advancing genetic testing and precision medicine technology.
Myriad Genetics's ticker is MYGN
The company's shares trade on the NASDAQ stock exchange
They are based in Salt Lake City, Utah
There are 1001-5000 employees working at Myriad Genetics
It is myriad.com
Myriad Genetics is in the Services sector
Myriad Genetics is in the Research Services industry
The following five companies are Myriad Genetics's industry peers: